JAMA 1984-05-04

Landmark article Sept. 21, 1946: Nitrogen mustard therapy. Use of methyl-bis(beta-chloroethyl)amine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. By Louis S. Goodman, Maxwell M. Wintrobe, William Dameshek, Morton J. Goodman, Alfred Gilman and Margaret T. McLennan.

L S Goodman, M M Wintrobe, W Dameshek, M J Goodman, A Gilman, M T McLennan

Index: JAMA 251(17) , 2255-61, (1984)

Full Text: HTML

Abstract

Related Compounds

Related Articles:

Identification of the nitrogen-based blister agents bis(2-chloroethyl)methylamine (HN-2) and tris(2-chloroethyl)amine (HN-3) and their hydrolysis products on soil using ion trap secondary ion mass spectrometry.

2000-12-01

[J. Mass Spectrom. 35(12) , 1460-9, (2000)]

Ameliorative effect of DRDE 07 and its analogues on the systemic toxicity of sulphur mustard and nitrogen mustard in rabbit.

2010-09-01

[Hum. Exp. Toxicol. 29(9) , 747-55, (2010)]

Carcinogenicity of trichloromethine hydrochloride (TS-160 Spofa) and morphological damage after its intraamniotic injection.

1981-01-01

[Neoplasma 28(5) , 565-74, (1981)]

Treatment of advanced Hodgkin's disease with modified MOPP regimens. A long-term observation.

1989-01-01

[Neoplasma 36(6) , 709-18, (1989)]

The effects of radiation and alkylating agents on chromatin degradation in normal and tumour lymphoid cells.

1991-02-01

[Gen. Physiol. Biophys. 10(1) , 41-8, (1991)]

More Articles...